GRI Bio, Inc. has reported a stock option grant to its director, David Leslie Szekeres, which took place on November 4, 2026. This move is significant as it underscores the company’s strategy to align executive interests with shareholder value in the competitive pharmaceutical preparations industry.
GRI Bio, Inc., trading under the ticker symbol GRI on the Nasdaq, is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is based in La Jolla, California, and operates as an emerging growth company.
The SEC filing indicates that Szekeres was granted stock options for 6,558 shares at an exercise price of $1.43 per share. The options will vest in four equal quarterly installments, fully vesting on the first anniversary of the grant date. This incentivizes Szekeres to contribute to the company's growth and success.
This stock option grant may affect the company’s strategic direction and its ability to attract and retain top talent in the pharmaceutical sector. Aligning the interests of directors with those of shareholders is a common practice that can enhance performance and accountability.
The filing does not specify what happens next regarding further actions or filings related to this grant.
The stock options granted to Szekeres are set to expire on November 4, 2036, providing a ten-year window for exercise. This long-term vesting schedule and expiration date are designed to encourage sustained commitment to the company's objectives.
Additionally, the filing details that Szekeres holds a direct ownership of the 6,558 shares following this transaction, indicating a personal stake in the company's performance. This further aligns his interests with those of the shareholders, as any increase in stock value would directly benefit him.
GRI Bio, Inc. was formerly known as Vallon Pharmaceuticals, Inc. until a name change on September 10, 2020, and it underwent another name change to its current title on April 24, 2023. This evolution reflects the company's strategic focus within the life sciences sector.
While the filing provides significant details regarding the stock option grant, it does not include any information about Szekeres's previous stock option grants or any potential plans for future grants or changes in his role within the company.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




